Display options
Cite
Jones BW, Pfeiffer RL, Ferrell WD, et al. Retinal Remodeling and Metabolic Alterations in Human AMD. Front Cell Neurosci. 2016;10:103doi: 10.3389/fncel.2016.00103.
Jones, B. W., Pfeiffer, R. L., Ferrell, W. D., Watt, C. B., Tucker, J., & Marc, R. E. (2016). Retinal Remodeling and Metabolic Alterations in Human AMD. Frontiers in cellular neuroscience, 10103. https://doi.org/10.3389/fncel.2016.00103
Jones, Bryan W, et al. "Retinal Remodeling and Metabolic Alterations in Human AMD." Frontiers in cellular neuroscience vol. 10 (2016): 103. doi: https://doi.org/10.3389/fncel.2016.00103
Jones BW, Pfeiffer RL, Ferrell WD, Watt CB, Tucker J, Marc RE. Retinal Remodeling and Metabolic Alterations in Human AMD. Front Cell Neurosci. 2016 Apr 28;10:103. doi: 10.3389/fncel.2016.00103. eCollection 2016. PMID: 27199657; PMCID: PMC4848316.
Copy Download .nbib Format: NLM
Share it on

Front Cell Neurosci. 2016 Apr 28;10:103. doi: 10.3389/fncel.2016.00103. eCollection 2016.

Retinal Remodeling and Metabolic Alterations in Human AMD.

Frontiers in cellular neuroscience

Bryan W Jones, Rebecca L Pfeiffer, William D Ferrell, Carl B Watt, James Tucker, Robert E Marc

Affiliations

  1. Department of Ophthalmology, Moran Eye Center, University of Utah Salt Lake City, UT, USA.
  2. Department of Ophthalmology, Moran Eye Center, University of UtahSalt Lake City, UT, USA; Interdepartmental Program in Neuroscience, University of UtahSalt Lake City, UT, USA.
  3. Department of Ophthalmology, University of California, Davis Davis, CA, USA.

PMID: 27199657 PMCID: PMC4848316 DOI: 10.3389/fncel.2016.00103

Abstract

Age-related macular degeneration (AMD) is a progressive retinal degeneration resulting in central visual field loss, ultimately causing debilitating blindness. AMD affects 18% of Americans from 65 to 74, 30% older than 74 years of age and is the leading cause of severe vision loss and blindness in Western populations. While many genetic and environmental risk factors are known for AMD, we currently know less about the mechanisms mediating disease progression. The pathways and mechanisms through which genetic and non-genetic risk factors modulate development of AMD pathogenesis remain largely unexplored. Moreover, current treatment for AMD is palliative and limited to wet/exudative forms. Retina is a complex, heterocellular tissue and most retinal cell classes are impacted or altered in AMD. Defining disease and stage-specific cytoarchitectural and metabolic responses in AMD is critical for highlighting targets for intervention. The goal of this article is to illustrate cell types impacted in AMD and demonstrate the implications of those changes, likely beginning in the retinal pigment epithelium (RPE), for remodeling of the the neural retina. Tracking heterocellular responses in disease progression is best achieved with computational molecular phenotyping (CMP), a tool that enables acquisition of a small molecule fingerprint for every cell in the retina. CMP uncovered critical cellular and molecular pathologies (remodeling and reprogramming) in progressive retinal degenerations such as retinitis pigmentosa (RP). We now applied these approaches to normal human and AMD tissues mapping progression of cellular and molecular changes in AMD retinas, including late-stage forms of the disease.

Keywords: Müller cell; age-related macular degeneration (AMD); computational molecular phenotyping (CMP); neural remodeling; photoreceptor; retina; retinal pigment epithelium (RPE); retinal remodeling

References

  1. Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2554-60 - PubMed
  2. J Biol Chem. 2014 May 23;289(21):14534-46 - PubMed
  3. Nature. 1977 Aug 18;268(5621):654-5 - PubMed
  4. PLoS One. 2010 Nov 08;5(11):e13885 - PubMed
  5. J Neurosci. 1995 Aug;15(8):5429-38 - PubMed
  6. J Neurosci. 2002 Jan 15;22(2):413-27 - PubMed
  7. J Comp Neurol. 1978 Nov 15;182(2):221-44 - PubMed
  8. Neuroscience. 1994 May;60(2):355-66 - PubMed
  9. Mol Vis. 2012;18:1197-214 - PubMed
  10. Invest Ophthalmol Vis Sci. 2000 Sep;41(10):3200-9 - PubMed
  11. J Neurosci. 2011 Nov 2;31(44):16033-44 - PubMed
  12. Prog Retin Eye Res. 2003 Sep;22(5):607-55 - PubMed
  13. Mol Interv. 2005 Aug;5(4):241-9 - PubMed
  14. J Neurosci. 2012 Nov 7;32(45):15715-27 - PubMed
  15. J Neurocytol. 2001 Jul;30(7):593-654 - PubMed
  16. Invest Ophthalmol Vis Sci. 1993 Dec;34(13):3661-8 - PubMed
  17. Ophthalmology. 2013 Apr;120(4):821-8 - PubMed
  18. Clin Exp Optom. 2005 Sep;88(5):282-91 - PubMed
  19. Clin Exp Optom. 2005 Sep;88(5):269-81 - PubMed
  20. Invest Ophthalmol Vis Sci. 1994 May;35(6):2843-9 - PubMed
  21. Vis Neurosci. 1994 Jul-Aug;11(4):793-804 - PubMed
  22. Eye (Lond). 2001 Jun;15(Pt 3):384-9 - PubMed
  23. Proc Natl Acad Sci U S A. 2005 May 17;102(20):7227-32 - PubMed
  24. Neurosci Lett. 1999 Mar 26;263(2-3):169-72 - PubMed
  25. Vision Res. 2003 Dec;43(28):2957-8 - PubMed
  26. Glia. 2005 Jan 15;49(2):184-96 - PubMed
  27. Br J Ophthalmol. 1999 Mar;83(3):358-68 - PubMed
  28. J Neurosci. 1996 Nov 1;16(21):6807-29 - PubMed
  29. Prog Brain Res. 1992;90:61-92 - PubMed
  30. J Neurosci. 1995 Jul;15(7 Pt 2):5106-29 - PubMed
  31. Ophthalmic Res. 1983;15(2):72-89 - PubMed
  32. Eye (Lond). 1988;2 ( Pt 5):552-77 - PubMed
  33. J Neurosci. 2002 Jul 1;22(13):5492-504 - PubMed
  34. Invest Ophthalmol Vis Sci. 2015 May;56(5):3253-68 - PubMed
  35. Invest Ophthalmol Vis Sci. 2001 Nov;42(12):3016-22 - PubMed
  36. Ophthalmic Res. 1996;28(2):99-107 - PubMed
  37. Vision Res. 2003 Apr;43(8):867-77 - PubMed
  38. J Neurosci. 1992 Apr;12(4):1169-93 - PubMed
  39. Hum Mol Genet. 2011 Apr 1;20(7):1387-99 - PubMed
  40. Vision Res. 1986;26(2):223-38 - PubMed
  41. Neuroscience. 2004;127(2):301-17 - PubMed
  42. Exp Eye Res. 2002 Sep;75(3):271-84 - PubMed
  43. Eye (Lond). 2001 Jun;15(Pt 3):376-83 - PubMed
  44. Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4481-8 - PubMed
  45. Clin Ophthalmol. 2008 Jun;2(2):413-24 - PubMed
  46. Am J Ophthalmol. 1994 Sep 15;118(3):368-76 - PubMed
  47. Prog Retin Eye Res. 2006 Jul;25(4):397-424 - PubMed
  48. Am J Ophthalmol. 2012 Mar;153(3):460-467.e1 - PubMed
  49. Am J Ophthalmol. 2000 Feb;129(2):215-23 - PubMed
  50. Exp Eye Res. 2011 Oct;93(4):413-23 - PubMed
  51. J Comp Neurol. 1996 Dec 16;376(3):343-60 - PubMed
  52. PLoS One. 2011;6(9):e23148 - PubMed
  53. Biofactors. 2003;17(1-4):161-73 - PubMed
  54. Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):11020-5 - PubMed
  55. Nat Genet. 2013 Apr;45(4):433-9, 439e1-2 - PubMed
  56. Retina. 2015 Jul;35(7):1465-73 - PubMed
  57. J Neurosci. 1990 Dec;10(12):4006-34 - PubMed
  58. Mol Vis. 2008 Apr 25;14:782-806 - PubMed
  59. Invest Ophthalmol Vis Sci. 1992 Jan;33(1):1-17 - PubMed
  60. Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2782-91 - PubMed
  61. Mol Neurobiol. 2003 Oct;28(2):139-47 - PubMed
  62. Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2280-90 - PubMed
  63. J Neurosci. 1981 Feb;1(2):152-65 - PubMed
  64. J Comp Neurol. 2011 Oct 1;519(14):2713-33 - PubMed
  65. Neurochem Res. 2004 Jan;29(1):151-60 - PubMed
  66. Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4759-65 - PubMed
  67. J Comp Neurol. 1993 Oct 8;336(2):174-93 - PubMed
  68. Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):473-8 - PubMed
  69. Science. 1975 May 30;188(4191):949-51 - PubMed
  70. Physiol Rev. 1992 Jan;72(1):101-63 - PubMed
  71. Neuroscience. 1996 Jan;70(1):295-302 - PubMed
  72. J Comp Neurol. 1985 Feb 8;232(2):241-60 - PubMed
  73. PLoS Biol. 2009 Mar;7(3):e1000074 - PubMed
  74. Invest Ophthalmol Vis Sci. 2014 Jul 17;55(8):4832-41 - PubMed
  75. Mol Immunol. 2009 May;46(8-9):1573-94 - PubMed
  76. Adv Exp Med Biol. 2006;572:405-10 - PubMed
  77. PLoS One. 2011 Apr 22;6(4):e18921 - PubMed
  78. Adv Exp Med Biol. 2014;801:229-35 - PubMed
  79. Am J Ophthalmol. 2012 Jun;153(6):1104-9.e2 - PubMed
  80. Eur J Biochem. 2000 Aug;267(16):4904-11 - PubMed
  81. Exp Eye Res. 2005 Aug;81(2):123-37 - PubMed
  82. J Comp Neurol. 1999 Apr 28;407(1):65-76 - PubMed
  83. Invest Ophthalmol Vis Sci. 2012 Apr 24;53(4):2193-8 - PubMed
  84. Invest Ophthalmol Vis Sci. 1995 Nov;36(12):2523-30 - PubMed
  85. Mol Vis. 2008;14:1784-91 - PubMed
  86. Invest Ophthalmol Vis Sci. 1998 Aug;39(9):1685-93 - PubMed
  87. Nat Genet. 2008 Jul;40(7):892-6 - PubMed
  88. Invest Ophthalmol Vis Sci. 2007 Jul;48(7):3364-71 - PubMed
  89. Invest Ophthalmol Vis Sci. 1998 Aug;39(9):1694-702 - PubMed
  90. Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4788-95 - PubMed
  91. J Neurosci. 2015 May 6;35(18):7304-11 - PubMed
  92. J Comp Neurol. 1999 Apr 28;407(1):47-64 - PubMed
  93. Invest Ophthalmol Vis Sci. 1989 Aug;30(8):1691-9 - PubMed
  94. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1976 Jul-Aug;81(4 Pt 1):OP687-93 - PubMed
  95. Exp Eye Res. 2001 Jun;72(6):661-6 - PubMed
  96. Br J Ophthalmol. 2011 Dec;95(12):1638-45 - PubMed
  97. Invest Ophthalmol Vis Sci. 1993 Nov;34(12):3278-96 - PubMed
  98. Exp Eye Res. 1999 Jun;68(6):693-702 - PubMed
  99. Arch Ophthalmol. 1969 Mar;81(3):383-94 - PubMed
  100. Jpn J Ophthalmol. 2012 Jul;56(4):289-306 - PubMed
  101. Invest Ophthalmol Vis Sci. 1996 Jun;37(7):1236-49 - PubMed
  102. J Comp Neurol. 2003 Sep 8;464(1):1-16 - PubMed
  103. Invest Ophthalmol Vis Sci. 2006 Aug;47(8):3579-85 - PubMed
  104. Mol Vis. 1999 Nov 03;5:32 - PubMed
  105. JAMA Ophthalmol. 2014 Mar;132(3):338-45 - PubMed
  106. Vis Neurosci. 1999 Nov-Dec;16(6):1169-80 - PubMed
  107. Science. 2006 Nov 10;314(5801):989-92 - PubMed

Publication Types

Grant support